These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 33249378)

  • 1. Diffuse alveolar hemorrhage as an early complication of alemtuzumab treatment: A case report of a multiple sclerosis patient and an overview of 14 cases.
    Drop BRH; Zemel D; Wokke BHA; van Oosten BW; Dik S; Martins Jarnalo CO; Westerweel PE; de Beukelaar JWK
    Mult Scler Relat Disord; 2021 Jan; 47():102614. PubMed ID: 33249378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diffuse alveolar hemorrhage during alemtuzumab infusion in a patient with multiple sclerosis: a case report.
    Myro AZ; Bjerke G; Zarnovicky S; Holmøy T
    BMC Pharmacol Toxicol; 2018 Nov; 19(1):75. PubMed ID: 30454022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ANCA-associated life-threatening systemic vasculitis after alemtuzumab treatment for multiple sclerosis.
    Horisberger A; Pantazou V; Cuendet G; Ribi C; Dunet V; Théaudin M
    Mult Scler; 2020 Oct; 26(12):1599-1602. PubMed ID: 32081100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis.
    Phelps R; Winston JA; Wynn D; Habek M; Hartung HP; Havrdová EK; Markowitz GS; Margolin DH; Rodriguez CE; Baker DP; Coles AJ
    Mult Scler; 2019 Aug; 25(9):1273-1288. PubMed ID: 30986126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A case of lung injury resembling diffuse pulmonary hemorrhage after the first administration of alemtuzumab in a patient with multiple sclerosis. Role of the HRCT.
    Cipolla G; Relo R; Pasciuta E; Catalano D; Lo Bello F; Coppolino I; Ruggeri P; Proietto A; Buccafusca M; Cutroneo PM; Trifirò G; Caramori G
    Monaldi Arch Chest Dis; 2020 Jul; 90(3):. PubMed ID: 32702962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alemtuzumab-induced simultaneous onset of autoimmune haemolytic anaemia, alveolar haemorrhage, nephropathy, and stroke: A case report.
    Alnahdi MA; Aljarba SI; Al Malik YM
    Mult Scler Relat Disord; 2020 Jun; 41():102141. PubMed ID: 32446212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alemtuzumab for relapsing multiple sclerosis in clinical practice: A four-year retrospective one-center study.
    Rodríguez de Castro B; Pampín Sánchez R; Tembrás Martinez S; Ayastuy Ruiz A; Martínez-Múgica Barbosa C
    Int J Risk Saf Med; 2020; 31(4):259-265. PubMed ID: 32145001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alemtuzumab-induced lung injury in multiple sclerosis: Learning from adversity in three patients.
    Bianco A; Mari PV; Larici AR; Lucchini M; Nociti V; Losavio FA; De Fino C; Cicchetti G; Coraci D; Richeldi L; Mirabella M
    Mult Scler Relat Disord; 2020 Jan; 37():101450. PubMed ID: 31675637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early neutropenia with thrombocytopenia following alemtuzumab treatment for multiple sclerosis: case report and review of literature.
    Maniscalco GT; Cerillo I; Servillo G; Napolitano M; Guarcello G; Abate V; Improta G; Florio C
    Clin Neurol Neurosurg; 2018 Dec; 175():134-136. PubMed ID: 30419425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alemtuzumab-associated diffuse alveolar damage - a case report.
    Bayas A; Menacher M; Schwaiblmair M; Märkl B; Naumann M
    BMC Neurol; 2020 Sep; 20(1):357. PubMed ID: 32967641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosis.
    Holmøy T; Fevang B; Olsen DB; Spigset O; Bø L
    BMC Res Notes; 2019 Aug; 12(1):497. PubMed ID: 31405369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic erythematous lupus after treatment of multiple sclerosis with alemtuzumab.
    Adamec I; Mayer M; Ćorić M; Ruška B; Habek M
    Mult Scler Relat Disord; 2020 Nov; 46():102589. PubMed ID: 33296985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-arm study to assess comprehensive infusion guidance for the prevention and management of the infusion associated reactions (IARs) in relapsing-remitting multiple sclerosis (RRMS) patients treated with alemtuzumab (EMERALD).
    Vukusic S; Brassat D; de Seze J; Izquierdo G; Lysandropoulos A; Moll W; Vanopdenbosch L; Arque MJ; Kertous M; Rufi P; Oreja-Guevara C
    Mult Scler Relat Disord; 2019 Apr; 29():7-14. PubMed ID: 30654246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alemtuzumab-induced Alopecia areata - a case report and systematic literature review of adverse events associated with Alemtuzumab.
    Dikeoulia E; Neufeld M; Pawlitzki M; Böhm M
    J Dtsch Dermatol Ges; 2021 Aug; 19(8):1159-1163. PubMed ID: 33973347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An unforeseen reality: Hemophagocytic lymphohistiocytosis following alemtuzumab treatment for a multiple sclerosis.
    Ošep AB; Brecl E; Škerget M; Savšek L
    Clin Neurol Neurosurg; 2023 May; 228():107675. PubMed ID: 36965418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hemophagocytic syndrome following alemtuzumab treatment for multiple sclerosis: A case report.
    Romero A; Midaglia L; Salcedo MT; Viladomiu L; Guillén E; Bajaña I; Escolà-Vergé L; Tintoré M; Montalban X; Len O
    Mult Scler Relat Disord; 2020 May; 40():101973. PubMed ID: 32028116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous early-onset immune thrombocytopenia and autoimmune thyroid disease following alemtuzumab treatment in relapsing-remitting multiple sclerosis.
    Obermann M; Ruck T; Pfeuffer S; Baum J; Wiendl H; Meuth SG
    Mult Scler; 2016 Aug; 22(9):1235-41. PubMed ID: 26980848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute myocardial infarction associated with initial alemtuzumab infusion cycle in relapsing-remitting multiple sclerosis.
    Romba MC; Newsome SD; McArthur JC
    Mult Scler Relat Disord; 2019 Sep; 34():100-102. PubMed ID: 31252364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum sickness (Like Reaction) in a patient treated with alemtuzumab for multiple sclerosis: A case report.
    Lapucci C; Gualandi F; Mikulska M; Palmeri S; Mancardi G; Uccelli A; Laroni A
    Mult Scler Relat Disord; 2018 Nov; 26():52-54. PubMed ID: 30223229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alemtuzumab-induced autoimmune thyroid events in patients with relapsing-remitting multiple sclerosis: A real-life and monocentric experience at a tertiary-level centre.
    Manso J; Zhu YH; Margoni M; Rinaldi F; Censi S; Carducci S; Cosma C; Plebani M; Gallo P; Mian C
    Clin Endocrinol (Oxf); 2022 Sep; 97(3):331-338. PubMed ID: 34724236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.